Clinical Trial Update: Acalabrutinib Real World Italian obSErvational Study -ARISE

View source ↗

Summary

An active, non-recruiting real-world observational study in Italy evaluating acalabrutinib for chronic lymphocytic leukemia (ARISE), sponsored by AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Lymphocytic Leukemia | Status: ACTIVE_NOT_RECRUITING